Synairgen (SNG)

 

SNG Share PerformanceMore

52 week high38.00 25/04/16
52 week low14.00 05/12/16
52 week change -9.76 (-39.43%)
4 week volume1,817,984 11/11/16

Media for (SNG)

Presenter: Richard Marsden, CEO
11/11/2014
Presenter: Richard Marsden
07/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 4682M Synairgen plc 13 October 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Synairgen plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or dis...

Synairgen updates on AZD9412

Synairgen (SNG) has confirmed that AstraZeneca has decided to stop the Phase IIa trial for AZD9412 based on an interim ...

FTSE up on airlines, house builders after sluggish start

London stocks shrugged offer an early sour start to be cautiously ahead, with both the blue-chip and mid-cap indices risin...

AZD9412 Clinical Trial Update

RNS Number: 2831M Synairgen plc 12 October 2016 Press release Synairgen plc ('Synairgen' or the 'Company') AZD9412 Clinical Trial Update ~ AstraZeneca to focus on key secondary endpoints with results expected in Q1 2017 ~ Southampton, UK - 12 October 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announced today t...

Broker Forecast - N+1 Singer issues a broker note on Synairgen PLC

N+1 Singer today reaffirms its buy investment rating on Synairgen PLC (LON:SNG) and cut its price target to 46p (from 4...

Synairgen widens H1 pretax loss

Synairgen has widened its H1 pretax loss to 1.7m, from a year-earlier loss of 1.0m. Revenue was nil, from 25,000. "We are ve...

Interim results for six months ended 30 June 2016

RNS Number: 5051K Synairgen plc 22 September 2016 Press release Synairgen plc ('Synairgen' or the 'Company') Interim results for the six months ended 30 June 2016 ~ Clinical development of AZD9412 with AstraZeneca on track and Pharmaxis collaboration progressing towards the clinic ~ Southampton, UK - 22 September 2016: Synairgen plc (LSE: SNG), the respir...

Notice of Interim Results

RNS Number: 2364J Synairgen plc 08 September 2016 PRESS RELEASE 8 September 2016 SYNAIRGEN PLC ("Synairgen" or "the Company") Notice of Interim Results Southampton, UK, 8 September 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, will issue its interim results for the six-month period ended 30 June 2016 o...

Fundamental DataMore

EPS-2.47
Dividend yield0 %

Equity Research (SNG)

edison investment research
Synairgen
14/07/2014
The recent exclusive global deal with AstraZeneca, potentially worth $230m, to in-license SNG001 for the treatment of asthma is a strong validation of Synairgen’s in-vitro cell-based approach using...

Latest discussion posts More

  • Re: FWIW

    -33% seems a massive overreaction to me. Ok it is not good news, but it is not as if they have scrapped the project. I will watch, wait and hold. Best, OP.
    12-Oct-2016
    Oofy Prosser
  • FWIW

    View from finn (I have no comment to add): Synairgen has announced this morning that AstraZeneca has decided to stop the Phase IIa trial for AZD9412 due to an unusually ...
    12-Oct-2016
    charlie51
  • Re: Fincap target 127p price 36p

    ... and the higher the better!!
    11-Aug-2016
    doc-lee

Users' HoldingsMore

Users who hold Synairgen also hold..
PREMIER OIL20%
CENTRICA16%
RENEURON16%
ANGLE16%
VECTURA16%

Codes & Symbols

ISINGB00B0381Z20
SymbolsSNG, LSE:SNG, SNG.L, SNG:LN, LON:SNG, XLON:SNG